Lion Street Advisors LLC Trims Stock Position in The Clorox Company $CLX

Lion Street Advisors LLC lessened its stake in shares of The Clorox Company (NYSE:CLX) by 2.8% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,125 shares of the company’s stock after selling 147 shares during the quarter. Lion Street Advisors LLC’s holdings in Clorox were worth $615,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of CLX. American National Bank & Trust lifted its position in shares of Clorox by 69.5% during the 2nd quarter. American National Bank & Trust now owns 217 shares of the company’s stock worth $26,000 after buying an additional 89 shares during the last quarter. Ransom Advisory Ltd purchased a new stake in shares of Clorox during the 1st quarter worth approximately $35,000. GW&K Investment Management LLC lifted its position in shares of Clorox by 239.1% during the 1st quarter. GW&K Investment Management LLC now owns 295 shares of the company’s stock worth $43,000 after buying an additional 208 shares during the last quarter. Ameritas Advisory Services LLC acquired a new position in shares of Clorox in the 2nd quarter valued at $48,000. Finally, Roble Belko & Company Inc increased its holdings in shares of Clorox by 140.7% in the 1st quarter. Roble Belko & Company Inc now owns 361 shares of the company’s stock valued at $53,000 after acquiring an additional 211 shares during the period. Hedge funds and other institutional investors own 78.53% of the company’s stock.

Clorox Stock Performance

Shares of CLX opened at $120.14 on Monday. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84. The stock has a market capitalization of $14.63 billion, a P/E ratio of 18.43, a P/E/G ratio of 0.98 and a beta of 0.52. The company’s fifty day moving average is $122.21 and its two-hundred day moving average is $128.57. The Clorox Company has a 1 year low of $116.53 and a 1 year high of $171.37.

Clorox (NYSE:CLX) last announced its quarterly earnings data on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.24 by $0.63. The company had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. Clorox’s revenue was up 4.5% compared to the same quarter last year. During the same period in the previous year, the company posted $1.82 EPS. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. On average, sell-side analysts predict that The Clorox Company will post 7.15 earnings per share for the current year.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, November 6th. Shareholders of record on Wednesday, October 22nd will be paid a $1.24 dividend. This represents a $4.96 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox’s payout ratio is currently 76.07%.

Insider Transactions at Clorox

In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of the business’s stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total value of $1,861,774.98. Following the transaction, the chief operating officer directly owned 54,221 shares of the company’s stock, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.57% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on CLX. Barclays cut their target price on shares of Clorox from $118.00 to $112.00 and set an “underweight” rating on the stock in a report on Tuesday, September 30th. Morgan Stanley cut their target price on shares of Clorox from $150.00 to $137.00 and set an “equal weight” rating on the stock in a report on Friday, August 1st. Citigroup cut their target price on shares of Clorox from $135.00 to $130.00 and set a “neutral” rating on the stock in a report on Wednesday, October 8th. Jefferies Financial Group cut their target price on shares of Clorox from $167.00 to $145.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Finally, UBS Group cut their target price on shares of Clorox from $134.00 to $128.00 and set a “neutral” rating on the stock in a report on Wednesday. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and three have given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and an average price target of $131.92.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.